Actinium Pharmaceuticals (ATNM) Q3 2025 earnings summary

Executive summary

• Report covers the quarter ended September 30, 2025, highlighting a strategic focus on targeted radiotherapies for cancer, with lead programs in solid tumors and hematology, and a pipeline prioritization to optimize resources.

• ATNM-400, a preclinical pan-tumor radiotherapy candidate, showed promising efficacy in prostate, lung, and breast cancer models, with new data presented at major scientific meetings.

• The company is seeking strategic partners for its hematology portfolio, including Iomab-B, Actimab-A, and Iomab-ACT, following regulatory feedback requiring additional trials for Iomab-B.

Financial highlights

• Net loss for the quarter was $5.1 million, a significant improvement from $11.6 million in the same quarter last year, primarily due to lower R&D and G&A expenses.

• For the nine months ended September 30, 2025, net loss was $27.9 million, down from $31.6 million year-over-year, reflecting reduced R&D spending.

• Cash and cash equivalents at quarter-end were $53.4 million, with no sales of common stock during the period.

• Operating cash outflow for the nine months was $19.3 million, down from $27.3 million in the prior year period.

• No commercial revenue was recognized; $0.1 million in grant revenue was recorded.

Outlook and guidance

• Management expects existing resources to fund operations for more than 12 months from the report date.

• Initial clinical data from Iomab-ACT trials and SCD studies are expected in the first half of 2026.

• The company is actively seeking partners for Iomab-B in the U.S. to execute required additional clinical trials.